Bo Lu

No. 628 Zhenyuan Road
Shenzhen, 518106, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphoma.

A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphoma.

Journal: Leukemia & lymphoma

Published: April 24, 2026

The PPTC7/BNIP3/NIX axis induces cGAS/STING-mediated senescence and augments CAR-T efficacy by repressing tumor-intrinsic mitophagy.

The PPTC7/BNIP3/NIX axis induces cGAS/STING-mediated senescence and augments CAR-T efficacy by repressing tumor-intrinsic mitophagy.

Journal: Journal of experimental & clinical cancer research : CR

Published: October 20, 2025

Super-Enhancer-Driven SOX4/SMAD3 Mediate Membrane Remodeling by Regulating Phospholipid Metabolism to Accelerate Leukemia Progression.

Super-Enhancer-Driven SOX4/SMAD3 Mediate Membrane Remodeling by Regulating Phospholipid Metabolism to Accelerate Leukemia Progression.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: July 04, 2025

Treatment outcomes of zanubrutinib-based regimen in newly diagnosed patients with MYC/BCL2 double-expressor diffuse large B-cell lymphoma: a retrospective multicenter real-world study.

Treatment outcomes of zanubrutinib-based regimen in newly diagnosed patients with MYC/BCL2 double-expressor diffuse large B-cell lymphoma: a retrospective multicenter real-world study.

Journal: Annals of hematology

Published: May 07, 2025

Prognostic Risk Model of Megakaryocyte-Erythroid Progenitor (MEP) Signature Based on AHSP and MYB in Acute Myeloid Leukemia.

Prognostic Risk Model of Megakaryocyte-Erythroid Progenitor (MEP) Signature Based on AHSP and MYB in Acute Myeloid Leukemia.

Journal: Biomedicines

Published: April 29, 2025

Current challenges and emerging opportunities of chimeric antigen receptor-engineered cell immunotherapy.

Current challenges and emerging opportunities of chimeric antigen receptor-engineered cell immunotherapy.

Journal: Experimental hematology & oncology

Published: March 24, 2025

SNRPB and CEP290, predicting the prognosis of diffuse large B cell lymphoma and associated with tumour immune microenvironment.

SNRPB and CEP290, predicting the prognosis of diffuse large B cell lymphoma and associated with tumour immune microenvironment.

Journal: Annals of medicine

Published: December 03, 2024

Upfront autologous hematopoietic stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma: A real-world multicenter study.

Upfront autologous hematopoietic stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma: A real-world multicenter study.

Journal: Journal of cancer research and therapeutics

Published: November 02, 2024

Construction of AML prognostic model with CYP2E1 and GALNT12 biomarkers based on golgi- associated genes.

Construction of AML prognostic model with CYP2E1 and GALNT12 biomarkers based on golgi- associated genes.

Journal: Annals of hematology

Published: August 14, 2024

Loss of Trim31 Worsens Cardiac Remodeling in a Mouse Model of Heart Failure by Enhancing the Activation of the NLRP3 Inflammasome.

Loss of Trim31 Worsens Cardiac Remodeling in a Mouse Model of Heart Failure by Enhancing the Activation of the NLRP3 Inflammasome.

Journal: Inflammation

Published: July 24, 2024

Construction of an acute myeloid leukemia prognostic model based on m6A-related efferocytosis-related genes.

Construction of an acute myeloid leukemia prognostic model based on m6A-related efferocytosis-related genes.

Journal: Frontiers in immunology

Published: July 27, 2023

Glutathione promotes the synergistic effects of venetoclax and azacytidine against myelodysplastic syndrome‑refractory anemia by regulating the cell cycle.

Glutathione promotes the synergistic effects of venetoclax and azacytidine against myelodysplastic syndrome‑refractory anemia by regulating the cell cycle.

Journal: Experimental and therapeutic medicine

Published: May 28, 2023

Showing 1-12 of 22

Last Updated: 09/26/2026